Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
2012 · New England Journal of Medicine · 7,903 citations
https://doi.org/10.1056/nejmoa1200694
K
Keith D. Eaton
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
166
Papers
12.2K
Citations
30
h-index
55
i10-index
Keith D. Eaton is an academic researcher from University of Washington. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Head and Neck Cancer Studies & Lung Cancer Research Studies. The author has an h-index of 30, co-authored 142 publications.
ORCID: 0000-0001-5025-2001Papers by this author
worksValidation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens
2013 · Journal of Molecular Diagnostics · 276 citations
https://doi.org/10.1016/j.jmoldx.2013.08.004
Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition
2019 · Science Signaling · 228 citations
https://doi.org/10.1126/scisignal.aau2922
Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma
2020 · Journal for ImmunoTherapy of Cancer · 53 citations
https://doi.org/10.1136/jitc-2020-001009
First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors
2022 · Investigational New Drugs · 40 citations
https://doi.org/10.1007/s10637-022-01274-y
Performance status (<scp>PS</scp>) as a predictor of poor response to immune checkpoint inhibitors (<scp>ICI</scp>) in recurrent/metastatic head and neck cancer (<scp>RMHNSCC</scp>) patients
2022 · Cancer Medicine · 25 citations
https://doi.org/10.1002/cam4.4722
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat